article · Heliyon
A dolutegravir-based regimen was more likely to result in patients achieving higher efficacy for viral suppression and a CD4<sup>+</sup> count increase. Although the differences were statistically insignificant, the mean AST and ALT levels were marginally higher in efavirenz-treated groups than in dolutegravir-treated groups.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.heliyon.2024.e33054
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
